This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Frénais, R. Articles by Krempf, M. Search for Related Content PubMed PubMed Citation Articles by Frénais, R. Articles by Krempf, M.

In Vivo Evidence for the Role of Lipoprotein Lipase Activity in the Regulation of Apolipoprotein AI Metabolism: A Kinetic Study in Control Subjects and Patients with Type II Diabetes Mellitus¹

Human Nutrition Research Center, INSERM, U-539 (R.F., H.N., K.O., C.M., J.M.B., T.M., M.K.), and Endocrinology, Metabolic Diseases, and Nutrition Clinic (Y.Z., B.C., M.K.), Hôtel Dieu, 44093 Nantes Cedex 01, France

Address all correspondence and requests for reprints to: Prof. M. Krempf, Clinique d’Endocrinologie, Maladies Métaboliques et Nutrition, Hôtel Dieu, 1 place A. Ricordeau, 44093 Nantes Cedex 01, France. E-mail: mkrempf{at}sante.univ-nantes.fr

The aim of this study was to delineate the role of lipoprotein lipase (LPL) activity in the kinetic alterations of high density lipoprotein (HDL) metabolism in patients with type II diabetes mellitus compared with controls. The kinetics of HDL were studied by endogenous labeling of HDL apolipoprotein AI (HDL-apo AI) using a primed infusion of D₃-leucine. The HDL-apo AI fractional catabolic rate (FCR) was significantly increased (0.32 ± 0.07 vs. 0.23 ± 0.05 pool/day; P < 0.01), and HDL composition was changed [HDL cholesterol, 0.77 ± 0.16 vs. 1.19 ± 0.37 mmol/L (P < 0.05); HDL triglycerides, 0.19 ± 0.12 vs. 0.10 ± 0.03 mmol/L (P < 0.05)] in diabetic patients compared with healthy subjects. HDL-apo AI FCR was correlated to plasma and HDL triglyceride concentrations (r = 0.82; P < 0.05 and r = 0.80; P < 0.05, respectively) and to homeostasis model assessment (r = 0.78; P < 0.05). Postheparin plasma LPL activity was decreased in type II diabetes (6.8 ± 2.8 vs. 18.1 ± 5.2 µmol/mL postheparin plasma·h; P < 0.005) compared with that in healthy subjects and was correlated to the FCR of HDL-apo AI (r = -0.63; P < 0.05). LPL activity was also correlated with HDL cholesterol (r = 0.78; P < 0.05), plasma and HDL triglycerides (r = -0.87; P < 0.005 and r = -0.83; P < 0.05, respectively), and homeostasis model assessment (r = -0.79; P < 0.05). In addition, the LPL to hepatic lipase ratio was correlated with the catabolic rate of HDL (r = -0.76; P < 0.06). These results suggest that a decrease in the LPL to hepatic lipase ratio in type II diabetes mellitus, mainly related to lowered LPL activity, could induce an increase in HDL catabolism. These alterations in HDL kinetics in type II diabetes proceed to some extent from changes in their composition, probably linked to an increase in triglyceride transfer from very low density lipoprotein particles, in close relationship with LPL activity and resistance to insulin.

This article has been cited by other articles:

				B. Verges, E. Florentin, S. Baillot-Rudoni, J.-M. Petit, M. C. Brindisi, J.-P. Pais de Barros, L. Lagrost, P. Gambert, and L. Duvillard Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes J. Lipid Res., June 1, 2009; 50(6): 1209 - 1215. [Abstract] [Full Text] [PDF]

				E. M. M. Ooi, G. F. Watts, P. J. Nestel, D. Sviridov, A. Hoang, and P. H. R. Barrett Dose-Dependent Regulation of High-Density Lipoprotein Metabolism with Rosuvastatin in the Metabolic Syndrome J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 430 - 437. [Abstract] [Full Text] [PDF]

				M. D. Jensen Adipose tissue as an endocrine organ: implications of its distribution on free fatty acid metabolism Eur. Heart J. Suppl., May 1, 2006; 8(suppl_B): B13 - B19. [Abstract] [Full Text] [PDF]

				J. Ji, G. F. Watts, A. G. Johnson, D. C. Chan, E. M. M. Ooi, K.-A. Rye, A. P. Serone, and P. H. R. Barrett High-Density Lipoprotein (HDL) Transport in the Metabolic Syndrome: Application of a New Model for HDL Particle Kinetics J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 973 - 979. [Abstract] [Full Text] [PDF]

				G. Bos, J. M Dekker, E. J. Feskens, M. C Ocke, G. Nijpels, C. D. Stehouwer, L. M Bouter, R. J Heine, and H. Jansen Interactions of dietary fat intake and the hepatic lipase -480C->T polymorphism in determining hepatic lipase activity: the Hoorn Study Am. J. Clinical Nutrition, April 1, 2005; 81(4): 911 - 915. [Abstract] [Full Text] [PDF]

				G. Bos, P. G. Scheffer, D. Vieira, J. M. Dekker, G. Nijpels, M. Diamant, T. Teerlink, C. D.A. Stehouwer, L. M. Bouter, R. J. Heine, et al. The Relationship of Lipoprotein Lipase Activity and LDL size Is Dependent on Glucose Metabolism in an Elderly Population: The Hoorn Study Diabetes Care, March 1, 2004; 27(3): 796 - 798. [Full Text] [PDF]

				M. C. Cheung, S. D. Sibley, J. P. Palmer, J. F. Oram, and J. D. Brunzell Lipoprotein lipase and hepatic lipase: their relationship with HDL subspecies Lp(A-I) and Lp(A-I,A-II) J. Lipid Res., August 1, 2003; 44(8): 1552 - 1558. [Abstract] [Full Text] [PDF]

				G. F. Watts, P. H. R. Barrett, J. Ji, A. P. Serone, D. C. Chan, K. D. Croft, F. Loehrer, and A. G. Johnson Differential Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate in Subjects With the Metabolic Syndrome Diabetes, March 1, 2003; 52(3): 803 - 811. [Abstract] [Full Text] [PDF]

				B. G. Brown, M. C. Cheung, A. C. Lee, X.-Q. Zhao, and A. Chait Antioxidant Vitamins and Lipid Therapy: End of a Long Romance? Arterioscler Thromb Vasc Biol, October 1, 2002; 22(10): 1535 - 1546. [Abstract] [Full Text] [PDF]